CSF Biomarker-Guided ABCA7 Therapeutic Dosing

Target: ABCA7 with biomarker-guided dosing Composite Score: 0.619 Price: $0.63▲1.2% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.619

Top 7% of 512 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

B+ Mech. Plausibility 15% 0.75 Top 38%

B+ Evidence Strength 15% 0.70 Top 34%

B Novelty 12% 0.60 Top 86%

A Feasibility 12% 0.85 Top 22%

B+ Impact 12% 0.70 Top 49%

A+ Druggability 10% 0.90 Top 16%

B+ Safety Profile 8% 0.75 Top 23%

B+ Competition 6% 0.70 Top 50%

A Data Availability 5% 0.80 Top 23%

A Reproducibility 5% 0.80 Top 20%

Evidence

6 supporting | 2 opposing

Citation quality: 0%

Debates

0 sessions

No debates yet

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function increases AD risk?

The abstract shows V1613M variant reduces amyloid plaques and damage in 5xFAD mice, yet ABCA7 loss-of-function mutations increase LOAD risk. This apparent contradiction suggests complex genotype-phenotype relationships that could inform therapeutic targeting. Gap type: contradiction Source paper: The Abca7 (None, None, PMID:38506634)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling

Score: 0.538 | Target: ABCA7 + TREM2 (combinatorial)

→ View full analysis & all 2 hypotheses

Description

Plasma GFAP and YKL-40 as companion biomarkers for ABCA7-targeted therapy dosing. Given that V1613M shows complex effects on lipid metabolism, therapeutic ABCA7 modulation requires biomarker-guided dosing to ensure efficacy while monitoring for potential cholesterol dysregulation side effects.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

8 citations 8 with PMID Validation: 0% 6 supporting / 2 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	PMIDs	Abstract
V1613M shows elevated circulating cholesterol and …	Supporting	-	-	-	PMID:38506634	-
ABCA7-LOF impacts phosphatidylcholine metabolism	Supporting	-	-	-	PMID:38979214	-
Plasma GFAP enables population-scale screening for…	Supporting	-	-	-	PMID:computational:ad_biomarker_registry	-
CSF/Plasma biomarker panel established: GFAP, YKL-…	Supporting	-	-	-	PMID:computational:ad_biomarker_registry	-
Lecanemab/donanemab efficacy validates amyloid bio…	Supporting	-	-	-	PMID:established_clinical	-
Biomarker-guided dosing is immediately actionable …	Supporting	-	-	-	PMID:feasibility_assessment	-
Premature without drug entity - biomarker strategy…	Opposing	-	-	-	PMID:skeptic:feasibility	-
GFAP/YKL-40 reflect downstream inflammation, not d…	Opposing	-	-	-	PMID:skeptic:critique	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 6

V1613M shows elevated circulating cholesterol and altered brain lipid composition requiring metabolic monitori…▼

V1613M shows elevated circulating cholesterol and altered brain lipid composition requiring metabolic monitoring

PMID:38506634

ABCA7-LOF impacts phosphatidylcholine metabolism

PMID:38979214

Plasma GFAP enables population-scale screening for reactive astrocytosis

PMID:computational:ad_biomarker_registry

CSF/Plasma biomarker panel established: GFAP, YKL-40, p-tau181, p-tau217, neurogranin

PMID:computational:ad_biomarker_registry

Lecanemab/donanemab efficacy validates amyloid biomarker approach

PMID:established_clinical

Biomarker-guided dosing is immediately actionable without requiring drug development

PMID:feasibility_assessment

✗ Opposing Evidence 2

Premature without drug entity - biomarker strategy requires known pharmacokinetics

PMID:skeptic:feasibility

GFAP/YKL-40 reflect downstream inflammation, not direct ABCA7 target engagement

PMID:skeptic:critique

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

7d Trend

↔

Stable

7d Momentum

▲ 1.2%

Volatility

Medium

0.0317

Events (7d)

⚡ Price Movement Log Recent 3 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.649	▼ 5.6%	evidence_update	2026-04-14 11:28
📄	New Evidence	$0.688	▲ 10.9%	evidence_update	2026-04-14 11:28
✨	Listed	$0.620		post_process	2026-04-14 11:28